Clinicians use olanzapine, mirtazapine, and other appetite-inducing medications off label to treat ARFID, but with little research to support their use. This study unpacks the potential role of medications in treating comorbid symptoms associated with ARFID. 

Catatonia is common in adult inpatient settings, where 6%–15% meet diagnostic criteria. In children and adolescents, prevalence estimates vary more widely, from 0.6% to 17%, perhaps because catatonia is often misdiagnosed or unrecognized. Like delirium, catatonia occurs as part of many conditions, including psychosis, mood disorders, substance use, autistic spectrum disorder, and medical conditions.

Richard Moldawsky, MD. Dr. Moldawsky, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study supports an association between short sleep duration in middle life and an increasedrisk of dementia.

This study suggests that patients started on pimavanserin for dementia and psychosis should probably continue it to prevent relapse, but we will need more data for clarity given flaws in the study design.

This study revealed no signal that trazodone protects against neurodegeneration.

We can continue to recommend ECT to patients with severe white matter hyperintensities and cognitive impairment, as cognition seems to return to baseline following ECT.

Numerous studies have established the efficacy of cognitive behavioral therapy (CBT) for a variety of psychiatric diagnoses. How effective CBT can be when delivered on a computer is an ongoing area of study. Here, researchers find that an internet-based CBT protocol was a helpful adjunctive treatment in a residential setting.

Problematic gambling is quite common, but many patients never receive any treatment. Hypothesizing that part of the reason for this is a lack of accessibility, researchers investigated the utility of internet-based gambling treatments. While not as effective as in-person treatment, the results were promising.

The period immediately following release from incarceration is associated with an elevated risk of overdose among those with opioid use disorder. In this randomized trial, researchers were able to show that long-acting injectable buprenorphine (Sublocade) is a feasible and effective treatment for this high-risk population.